A CXCR4-targeted immunomodulatory nanomedicine for photodynamic amplified immune checkpoint blockade therapy against breast cancer
Source abstract
Abstract
The therapeutic efficacy of immune checkpoint blockade (ICB) is critically compromised by inadequate T lymphocyte infiltration, low T cell-induced pro-inflammatory responses, and the accumulation of immunosuppressive cells within the tumor microenvironment (TME). In this work, a chimeric peptide-engineered immunomodulatory nanomedicine (designated as CXNP-CeBM) is developed for photodynamic amplified ICB therapy against breast cancer. CXNP-CeBM is composed of a CXCR4-targeting peptide ((C16)2-KLGASWHRPDK) loaded with the photosensitizer of Ce6 and the PD-1/PD-L1 inhibitor of BMS8. CXNP-CeBM specifically recognizes CXCR4 on breast cancer, thus suppressing CXCR4-mediated signaling pathways and enhancing the intracellular delivery of therapeutic agents. The photodynamic therapy (PDT) of CXNP-CeBM damages primary tumor cells to initiate immunogenic cell death (ICD), leading to the release of high mobility group box 1 (HMGB1) and the exposure of calreticulin (CRT). Simultaneously, the interruption of CXCR4 signaling reduces tumor fibrosis, promotes T-cell infiltration, and decreases the number of immunosuppressive cells, thereby enhancing the immunotherapeutic effect of ICB. Treatment with CXNP-CeBM would activate systemic anti-tumor immunity, leading to effective inhibition of both primary and lung metastatic tumors, while maintaining low systemic toxicity. This work provides a reliable strategy for the delivery of multi-synergistic agents, effectively activating breast cancer immunity through a multifaceted mechanism. STATEMENT OF SIGNIFICANCE: Although immune checkpoint blockade (ICB) has shown great potential for malignant tumor therapy, its efficacy is compromised by immunosuppressive microenvironments. Herein, a CXCR4-targeted immunomodulatory nanomedicine (CXNP-CeBM) was constructed for photodynamic amplified ICB therapy of breast cancer. CXNP-CeBM could selectively deliver photosensitizers and PD-1/PD-L1 inhibitors to breast cancer cells that overexpressed the chemokine receptor CXCR4, while interrupting CXCR4 signaling to reduce tumor fibrosis, promote T-cell infiltration, and decrease the number of immunosuppressive cells. Moreover, CXNP-CeBM induced photodynamic therapy to trigger immunogenic cell death while downregulating the PD-L1 level to destroy immune evasion mechanisms, thus activating immunological cascades to treat both primary and lung metastatic tumors. This study provided a multi-synergistic strategy for breast cancer immunotherapy through a multifaceted mechanism.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Canscreen 5, a global repository for breast, cervical and colorectal cancer screening programs10.1038/s41591-023-02315-6 ↗
2. Breast cancer: an up-to-date review and future perspectives10.1002/cac2.12358 ↗
3. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. The cutting-edge progress of immune-checkpoint blockade in lung cancer10.1038/s41423-020-00577-5 ↗
5. The interaction of CD4 (+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response
6. Boosting checkpoint immunotherapy with biomaterials10.1021/acsnano.2c11691 ↗
7. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy10.1016/j.apsb.2022.11.001 ↗
8. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response10.1038/s41392-022-01136-2 ↗
9. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
10. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
11. CD8+ T cell differentiation and dysfunction in cancer10.1038/s41577-021-00574-3 ↗
12. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
13. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
14. Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death10.1016/j.cclet.2021.10.074 ↗
15. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy10.1038/s41551-018-0203-4 ↗
16. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy10.1038/s41467-018-04703-w ↗
17. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death
18. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy10.1038/ncomms12499 ↗
19. Targeting immunogenic cell stress and death for cancer therapy
20. How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?10.7150/thno.72465 ↗
21. Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy10.1016/j.mtadv.2022.100276 ↗
22. Electromagnetic nanomedicines for combinational cancer immunotherapy10.1002/anie.202008386 ↗
23. A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence10.1126/sciadv.abq8225 ↗
24. How chemokines organize the tumour microenvironment10.1038/s41568-023-00635-w ↗
25. The dynamic roles of the bladder tumour microenvironment10.1038/s41585-022-00608-y ↗
26. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling10.1186/s12964-018-0233-2 ↗
27. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets10.1186/s13045-022-01282-8 ↗
28. CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis10.1016/j.lfs.2020.117534 ↗
29. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
30. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts10.1016/j.addr.2021.02.012 ↗
31. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma10.1038/s41419-022-05351-1 ↗
32. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy10.1016/j.apsb.2020.08.010 ↗
33. Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer10.1073/pnas.1710754114 ↗
34. Cancer nanotechnology: a new revolution for cancer diagnosis and therapy10.2174/1389200219666180918111528 ↗
35. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance10.1016/j.biomaterials.2022.121523 ↗
36. Aggregation-induced emission: recent advances in materials and biomedical applications10.1002/anie.202000845 ↗
37. Carrier-free nanodrug for the chemical-photodynamic synergistic treatment of lung cancer10.1021/acsanm.4c00659 ↗
38. Highly effective generation of singlet oxygen by an imidazole-linked robust photosensitizing covalent organic framework10.1021/acsnano.2c10423 ↗
39. Cell membrane as a promising therapeutic target: from materials design to biomedical applications
40. A novel chimeric oncolytic virus mediates a multifaceted cellular immune response in a syngeneic B16 melanoma model
41. Nanoplatform-based strategies for enhancing the lethality of current antitumor PDT10.1039/D4TB00008K ↗
42. Review of dendritic cells, their role in clinical immunology, and distribution in various animal species10.3390/ijms22158044 ↗
43. Dendritic cells and CD8 T cell immunity in tumor microenvironment10.3389/fimmu.2018.03059 ↗
44. The role of photodynamic therapy in triggering cell death and facilitating antitumor immunology10.3389/fonc.2022.863107 ↗
45. Immunogenic cell death in hematological malignancy therapy
46. Engineering nanomedicines for immunogenic eradication of cancer cells: recent trends and synergistic approaches10.1016/j.apsb.2024.03.022 ↗
47. Endoplasmic reticulum stress and the unfolded protein response: emerging regulators in progression of traumatic brain injury10.1038/s41419-024-06515-x ↗
48. Which cell death modality wins the contest for photodynamic therapy of cancer?10.1038/s41419-022-04851-4 ↗
49. Regulatory mechanisms of PD-1/PD-L1 in cancers10.1186/s12943-024-02023-w ↗
50. Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1/PD-L1 pathway10.1021/acs.jmedchem.3c02143 ↗
51. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy10.1021/acsami.0c21743 ↗
52. Tissue density in the progression of breast cancer: bedside to bench and back again
53. Mechanisms of fibrosis: therapeutic translation for fibrotic disease10.1038/nm.2807 ↗
54. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer10.1073/pnas.1815515116 ↗
55. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
56. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks10.1038/onc.2015.139 ↗
57. Extramedullary hematopoiesis of the liver and spleen10.3390/jcm10245831 ↗
58. Melanin-based immunoregulatory nanohybrids enhance antitumor immune responses in breast cancer mouse model10.1021/acsnano.3c02287 ↗